Nanosonics Advances CORIS Into Three Markets With FY27 Launch in Sight
CORIS commercialisation milestones advancing across three markets
Nanosonics Limited (ASX: NAN) has provided an update on key CORIS commercialisation milestones, confirming concurrent progress across three geographies. The company has filed its second FDA 510(k) submission to expand endoscope indications, installed its first Australian Controlled Market Release (CMR) unit, and confirmed its UK CMR is progressing in line with expectations. Taken together, the milestones reflect disciplined, phased execution toward broader commercialisation targeted for FY27.
When big ASX news breaks, our subscribers know first
Three milestones, three markets — what’s happening and where
Second FDA 510(k) submission filed
Nanosonics has submitted its second FDA 510(k) application, designed to support further expansion of CORIS endoscope indications. This follows the previously announced first 510(k) clearance and represents continued progress in building a broad range of endoscope indications as part of the broader commercialisation strategy. Each additional clearance widens the pool of endoscope types the system can address commercially.
Australia: first CMR unit installed
The first CORIS unit has been installed at an Australian hospital, with staff currently undergoing training. CMR commencement is expected shortly. Additional Australian sites are planned to come online progressively as the programme expands.
UK and Ireland CMR on track
The UK CMR remains underway, with CORIS operating in line with expectations. Additional sites in Australia and Ireland are planned to come online progressively, with US CMR activities to follow initial learnings from these early deployments.
Michael Kavanagh, CEO & President of Nanosonics
“We are making good progress across our phased commercialisation plan for CORIS. The submission of our second 510(k), together with the advancement of our CMR programs, reflects disciplined execution against our regulatory and market entry strategy.”
What is the CORIS system and why does it matter?
CORIS is a novel technology designed to reduce infection risk and enhance patient safety by delivering improved cleaning outcomes for flexible endoscopes. It specifically targets the complex internal channels of endoscopes, which are particularly prone to biofilm build-up. Biofilm is a thin layer of bacteria that can accumulate on surfaces inside medical instruments and is notoriously difficult to remove with standard cleaning methods.
Through an automated mechanism of action, CORIS combines cutting-edge science and engineering with practical usability to address what is recognised as one of the most critical challenges in medical device reprocessing today. The system is built to integrate into existing hospital workflows without placing excessive operational burden on clinical staff.
A CMR, or Controlled Market Release, is the first step of Nanosonics’ phased commercialisation of the CORIS system. It involves a strategically limited launch into select user environments to generate real-world feedback, helping the company identify and resolve any potential unexpected issues prior to broader commercialisation in FY27. For investors, the CMR phase functions as the bridge between regulatory clearance and full commercial scale. Data gathered now directly informs the confidence and readiness of the FY27 launch.
| Market | CMR Status | Current Activity | Next Step | Timeline Signal |
|---|---|---|---|---|
| Australia | Unit installed | Clinical training underway | CMR commencement | Imminent |
| United Kingdom | Underway | CORIS operating in line with expectations | Progressive site additions | Ongoing |
| Ireland | Planned | Pre-launch preparation | Sites to come online progressively | Progressive |
| United States | Pre-CMR | Monitoring early deployment learnings | CMR activation | Follows early market learnings |
The next major ASX story will hit our subscribers first
What this means for the investment case
Phased commercialisation de-risking the path to FY27
The structured, multi-market CMR approach reflects deliberate risk management on Nanosonics’ part. By gathering real-world operational data across Australia, the UK, and Ireland before scaling, management is able to refine the commercial model ahead of the FY27 broader launch, reducing the likelihood of material disruptions at scale.
The second 510(k) submission is also strategically meaningful. Expanding the range of cleared endoscope indications broadens the addressable market for CORIS, increasing the number of hospital settings and procedure types the system can serve commercially. This directly supports the revenue opportunity available at full launch.
More broadly, Nanosonics operates in a structural growth market. As patient safety standards tighten globally and regulatory scrutiny of infection control in medical settings intensifies, demand for validated reprocessing technologies is expected to grow over time.
Investors tracking the CORIS programme should monitor the following near-term catalysts:
- Second 510(k) FDA clearance outcome
- CMR commencement in Australia following training completion
- Progressive site additions across Australia and Ireland
- US CMR activation, informed by early deployment learnings
- Broader commercialisation in FY27
Don’t Miss the Next Healthcare Breakout on the ASX
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis already done for you. Over 20,000 active subscribers rely on it to stay ahead of market-moving announcements. Click the “Free Alerts” button to start receiving alerts the moment ASX healthcare news breaks.